| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: present invention refers to a piperazine compound presented by formula , wherein R 1 represents C 1-6 alkyl; R 2 represents hydroxy, C 1-6 alkyl which can contain a substitute specified in saturated or unsaturated 5-6 member heterocycle with 1-3 heteroatoms specified in oxygen and nitrogen, -(C=O)-N(R 3 )(R 4 ) or -(C=O)-OR 5 ; R 3 and R 4 may be identical or different, and each represents hydrogen or C 1-6 alkyl which can contain a substitute specified in saturated or unsaturated 5-6 member heterocycle with 1-3 heteroatoms specified in oxygen and nitrogen, or R 3 and R 4 bound through a nitrogen atom whereto R 3 and R 4 are attached, can form a saturated heterocyclic group specified in 5-6 member heterocycle with 1-3 heteroatoms specified in oxygen and nitrogen; R 5 represents hydrogen or C 1-6 alkyl; and n represents 1 or 2; or a salt thereof. Also, the invention refers to a pharmaceutical compositions and an agent exhibiting prostaglandin-D-synthase activity and based on the compound of formula I, as well as to a method of preventing and treating a disease wherein prostaglandin D2 is involved. n EFFECT: there are prepared and described new compounds which may be effective in treating the diseases wherein prostaglandin D2 is involved. n 11 cl, 19 ex, 4 tbl |